Replies to post #59251 on PharmaCyte Biotech Inc (PMCB)

[Ciab]

wow Rudy, so I believe this was the case for the CiaB/Melligen Cells patent...cool

Besides in vivo use, encapsulation of antibody or antibody like producing cells can be of great interest for the industrial production of antibodies by the biotech industry. The capsules can act as a pre-filtration device and eliminate cost-intensive steps during downstream processing of antibody products. Such encapsulated products should be seen favourably by industry since they may allow for new IP surrounding old technologies in combination with capsules. This may allow generation of new patents or extension of old patents, something it can be assumed is much needed when looking at the current portfolios of many of the large pharmaceutical companies.

[Ciab]

awesome...sorry if this has already been posted

"...Capsules may be dissolved in vitro prior to use in order to release the cells or implanted directly as capsules into the patient, depending on the application. The cellulose sulphate encapsulation technology Cell-in-a-Box® developed by the company SG Austria Pte Ltd/Austrianova Singapore Pte Ltd in Singapore allows for cryopreservation of capsules containing cells [4]. Frozen capsules can be stored for many months without appreciable loss of cell viability; an attribute that makes cellulose sulphate desirable over other more commonly used encapsulation technologies such as alginate which cannot be frozen (Fig. 6). This attribute has a high commercial value since cells can be frozen at -80°C for storage in chest freezers or transport on dry ice or at lower temperatures between -150 and -178°C which allows storage and/or transport under the gas phase of liquid nitrogen. Both are equally viable using cellulose sulphate. This long-term storage and long-distance transport option makes product validation and distribution possible, which are both necessary for the development of a mass production of a medical product...."